Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24811087 | 0.97 | NAMPT (0.38) | NAMPTASAH1DRD2DRD3TRPV1 | |
| SCHEMBL24809756 | 0.82 | ASAH1 (0.36) | ASAH1DRD2DRD3BRD4 | |
| SCHEMBL24809412 | 0.82 | BRD4 (0.36) | ASAH1BRD4 | |
| SCHEMBL24809462 | 0.81 | MTNR1A (0.33) | MEN1KMT2ADRD2 | |
| SCHEMBL24809410 | 0.80 | HPGD (0.38) | NAMPTASAH1MEN1KMT2A | |
| SCHEMBL24809407 | 0.80 | ASAH1 (0.54) | ASAH1 | |
| SCHEMBL24809461 | 0.79 | DRD2 (0.33) | NAMPTASAH1DRD2DRD3 | |
| SCHEMBL24810568 | 0.79 | L3MBTL1 (0.48) | ASAH1MEN1KMT2ADRD2DRD3 | |
| SCHEMBL24810656 | 0.78 | HPGDS (0.36) | KMT2A | |
| SCHEMBL24809346 | 0.77 | ASAH1 (0.38) | ASAH1MEN1KMT2ATRPV1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-29 | — | — | US | disclosed |
| EP-4031531-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| CN-114787135-A | Substituted imidazole carboxamides and their use in the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, CLN6 | NAMPT 175/4885ASAH1 16/4885MEN1 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.